Fosamax is a brand name of alendronate, approved by the FDA in the following formulation(s):
FOSAMAX (alendronate sodium - solution; oral)
Manufacturer: MERCK
Approval date: September 17, 2003
Strength(s): EQ 70MG BASE/75ML [RLD]
FOSAMAX (alendronate sodium - tablet; oral)
Manufacturer: MERCK AND CO INC
Approval date: September 29, 1995
Strength(s): EQ 10MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: MERCK AND CO INC
Approval date: April 25, 1997
Strength(s): EQ 5MG BASE [AB]
Manufacturer: MERCK AND CO INC
Approval date: October 20, 2000
Strength(s): EQ 35MG BASE [AB], EQ 70MG BASE [RLD][AB]
Has a generic version of Fosamax been approved?
A generic version of Fosamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fosamax and have been approved by the FDA:
alendronate sodium tablet; oral
Manufacturer: APOTEX
Approval date: August 4, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: AUROBINDO PHARMA
Approval date: August 4, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: AUSTARPHARMA LLC
Approval date: September 24, 2009
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: CADISTA PHARMS
Approval date: February 18, 2010
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: August 4, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: MYLAN
Approval date: August 4, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: SUN PHARMA GLOBAL
Approval date: September 10, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: TEVA PHARMS
Approval date: February 6, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 40MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB]
Manufacturer: WATSON LABS
Approval date: August 4, 2008
Strength(s): EQ 10MG BASE [AB], EQ 35MG BASE [AB], EQ 35MG BASE [AB], EQ 40MG BASE [AB], EQ 40MG BASE [AB], EQ 5MG BASE [AB], EQ 70MG BASE [AB], EQ 70MG BASE [AB]
Note: No generic formulation of the following product is available.
- alendronate sodium - solution; oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Dry mix formulation for bisphosphonic acids with lactose
Patent 5,358,941
Issued: October 25, 1994
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Patent expiration dates:
- December 2, 2012
- June 2, 2013✓
- December 2, 2012
Oral liquid alendronate formulations
Patent 5,462,932
Issued: October 31, 1995
Inventor(s): Brenner; Gerald S. & Katdare; Ashok V. & Pretzer; Denise & Whiteford; Donna T.
Assignee(s): Merck & Co., Inc.
Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.Patent expiration dates:
- May 17, 2014
- November 17, 2014✓
- May 17, 2014
Dry mix formulation for bisphosphonic acids
Patent 5,681,590
Issued: October 28, 1997
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Patent expiration dates:
- December 2, 2012
- June 2, 2013✓
- December 2, 2012
Method for inhibiting bone resorption
Patent 5,994,329
Issued: November 30, 1999
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Patent expiration dates:
- July 17, 2018✓
- January 17, 2019✓
- July 17, 2018
Method for inhibiting bone resorption
Patent 6,015,801
Issued: January 18, 2000
Inventor(s): Daifotis; Anastasia G. & Yates; A. John & Santora, II; Arthur C.
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.Patent expiration dates:
- July 17, 2018✓
- January 17, 2019✓
- July 17, 2018
Dry mix formulation for bisphosphonic acids
Patent 6,090,410
Issued: July 18, 2000
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Patent expiration dates:
- December 2, 2012
- June 2, 2013✓
- December 2, 2012
Dry mix formulation for bisphosphonic acids
Patent 6,194,004
Issued: February 27, 2001
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Patent expiration dates:
- December 2, 2012
- June 2, 2013✓
- December 2, 2012
Method for inhibiting bone resorption
Patent 6,225,294
Issued: May 1, 2001
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Patent expiration dates:
- July 17, 2018✓
- January 17, 2019✓
- July 17, 2018
See also...
- Fosamax Consumer Information (Drugs.com)
- Fosamax Consumer Information (Wolters Kluwer)
- Fosamax Solution Consumer Information (Wolters Kluwer)
- Fosamax Consumer Information (Cerner Multum)
- Fosamax Advanced Consumer Information (Micromedex)
- Fosamax AHFS DI Monographs (ASHP)
- Alendronate Consumer Information (Wolters Kluwer)
- Alendronate Solution Consumer Information (Wolters Kluwer)
- Alendronate Consumer Information (Cerner Multum)
- Alendronate Advanced Consumer Information (Micromedex)
- Alendronate Sodium AHFS DI Monographs (ASHP)
No comments:
Post a Comment